FOLFOX is a Combination Chemotherapy Regimen
FOLFOX is a combination chemotherapy regimen consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin 1.
Regimen Components and Administration
The FOLFOX regimen combines three cytotoxic agents:
- 5-Fluorouracil (5-FU): A fluoropyrimidine chemotherapy agent administered both as a bolus and continuous infusion
- Leucovorin (LV): Also called folinic acid, which enhances 5-FU activity
- Oxaliplatin: A platinum-based chemotherapy agent
The typical FOLFOX dosing schedule includes oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-FU bolus 400 mg/m², followed by 5-FU 2400 mg/m² as a continuous 46-hour infusion, administered every 2 weeks 2, 3.
Clinical Applications
FOLFOX is primarily used as a combination chemotherapy regimen for gastrointestinal malignancies, with the strongest evidence supporting its use in:
Colorectal Cancer
- First-line treatment for advanced/metastatic disease: FOLFOX provides higher response rates, longer progression-free survival, and better overall survival compared to 5-FU/LV alone 1
- Adjuvant therapy for stage III colon cancer: FOLFOX combinations are superior to single-agent 5-FU in terms of disease-free survival and overall survival 4
- Perioperative therapy for resectable liver metastases: Improves progression-free survival by 7-8% at 3 years 1
Gastric and Gastroesophageal Junction Cancers
FOLFOX is a preferred regimen for HER2-negative disease, showing reduced toxicity and similar efficacy compared to fluorouracil plus cisplatin, with particular benefit in older adult patients (>65 years) 2.
Comparison with Alternative Regimens
FOLFOX and FOLFIRI (5-FU/leucovorin/irinotecan) have similar activity but different toxicity profiles 1:
- FOLFOX: More polyneuropathy (peripheral sensory neuropathy)
- FOLFIRI: More alopecia and febrile neutropenia
CAPOX (capecitabine plus oxaliplatin) can be used interchangeably with FOLFOX 3, 1, offering the advantage of oral administration without requiring central venous access.
Key Toxicity Management
The most clinically significant toxicity is oxaliplatin-induced peripheral sensory neuropathy. Management strategies include:
- Discontinue oxaliplatin after 3 months of therapy (or sooner for unacceptable neurotoxicity) while maintaining other drugs in the regimen 3, 5
- This "stop-and-go" approach (OPTIMOX1 strategy) decreases neurotoxicity without affecting overall survival
- Do not use calcium/magnesium infusions for neuropathy prevention—they are ineffective 3
Important Clinical Distinctions
FOLFOX is a doublet chemotherapy regimen (two cytotoxic agents: fluoropyrimidine + oxaliplatin), distinct from:
- Triplet regimens like FOLFOXIRI (adds irinotecan), which show improved efficacy but significantly increased toxicity 6
- Single-agent fluoropyrimidine therapy, which remains appropriate for frail or elderly patients where combination therapy may not be tolerated 1
The regimen can be combined with targeted biologic agents (bevacizumab, cetuximab, panitumumab) depending on tumor molecular characteristics and treatment goals 1.